Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.91 USD
-0.07 (-6.68%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $0.92 +0.01 (1.10%) 5:04 PM ET
3-Hold of 5 3
F Value A Growth A Momentum C VGM
Brokerage Reports
Sangamo Therapeutics, Inc. [SGMO]
Reports for Purchase
Showing records 201 - 220 ( 323 total )
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 24
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2:15 Results: $218MM Cash Covers Significant Clinical Progress and Recommend Buying on Weakness for 2016 Horizon
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
July and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Emerging Pharmaceuticals - June and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Progress: Changes to Beta- Thalassemia Approach and ASGCT Presentations for HIV and ZFN Mechanisms; Reiterate OUTPERFORM and $30 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 11th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
May and 2015 Emerging Pharmaceuticals Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 27th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials: Plenty of Cash to Cover Active Pipeline; Reiterate OUTPERFORM and $30 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 6th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
April and 2015 Emerging Pharmaceuticals CatalystsThis report contains brief updates on the following: BIOD, BMRN, ICPT, LXRX, OMER, RCPT, RLYP, SGMO, VTAE, XOMA. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
March and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
March and 2015 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Data at CROI Further Validates ZFN CCR5 Deletion as a Method to Induce HIV Viremia Control
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ZFN In Vivo Protein Replacement Preclinical Data Suggests to Us a Potential Cure for Lysosomal Storage Diseases; Reiterate OUTPERFORM and $30 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY 2014 Financials: Long Cash Runway and Clinical Catalysts in 2015; Reiterate OUTPERFORM and Increase PT to $30 for Time Value
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sangamo Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L